Association of Radioactive Iodine Administration With Outcome Among Patients With Low‐Risk Differentiated Thyroid Cancer: A Real‐World Data Analysis
Authors' conclusion
Administering RAI ablation following TT did not result in improved DFS for low-risk DTC patients. Our findings suggest that decisions regarding RAI should be made judiciously to avoid overtreatment in this clinical scenario.
Study context
- Population
- Low-risk differentiated thyroid cancer (DTC) patients after total or near-total thyroidectomy (TT), tertiary medical centre, January 2008–July 2018matched cohort: 135 vs 204
- Participants
- 720 patients
- Exposure
- Radioactive iodine (RAI) vs no RAI after TT
- Outcome
- Disease-free survival (DFS) (structural persistent/recurrent disease)
- Follow-up
- 5 years
Methodological detailspropensity-score matched, single tertiary centre, Median follow-up 59.5 months
- Propensity-score matched
- Single tertiary centre
- Median follow-up 59.5 months
Main finding
5-year DFS rate
Hazard ratio
0.29
95% CI 0.06–1.37
P = 0.118
By group
RAIvs non-RAI
HR 0.29 (95% CI 0.06–1.37); P = 0.118
As reported in the abstract
Observational data: associations, not effects.
Further findings
5-year DFS rate, entire cohort (before matching)
P = 0.704
Subgroup analyses
- RAI ablation did not significantly reduce the risk of structural persistent/recurrent disease in subgroups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Association of Radioactive Iodine Administration With Outcome Among Patients With Low‐Risk Differentiated Thyroid Cancer: A Real‐World Data Analysis. Clin Endocrinol (Oxf). Published 23 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →